Latest news with #JohnGill
Yahoo
7 days ago
- Business
- Yahoo
Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ('Eledon') (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be presented by Dr. John Gill from the University of British Columbia. Details of the oral presentation are as follows: Title: Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b StudySession: Oral Presentation, Kidney Novel Immunosuppressant StrategiesPresenter: John Gill, MD, MS, University of British Columbia, Vancouver, CanadaSession Date and Time: Wednesday, August 6, 2025: 10:00 a.m. – 11:15 a.m. PT Following the session, a copy of the presentation can be found on the Investor section of the Company's website at The Company will also sponsor a satellite symposium at WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?', to be held on Sunday, August 3, at 1:00 pm PT. Faculty include Allan Kirk, MD, Duke University School of Medicine, Oriol Bestard, MD, PhD, MD, Vall d'Hebron University Hospital, John Gill, MD, MS, University of British Columbia, Alexandre Loupy, MD, PhD, Necker Hospital and Deirdre Sawinski, MD, Weill Cornell Medical College. In addition to the oral presentation, new preclinical data, utilizing tegoprubart for the prevention of rejection in non-human primates undergoing liver transplantation, will be presented by Dr. Andrew Adams in a poster session: Title: Anti-CD154 Facilitates Long-Term Liver Allograft Survival in Non-Human PrimatesSession: Poster PresentationPresenter: Andrew Adams, MD, PhD, University of MinnesotaDate and Time: Sunday, August 3, 2025, 3:30 p.m. PT About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter Investor Contact: Stephen JasperGilmartin Group(858) 525 2047stephen@ Media Contact: Jenna UrbanCG Life(212) 253 8881jurban@ Source: Eledon Pharmaceuticals
Yahoo
20-06-2025
- Business
- Yahoo
Hyatt Centric property in Chicago reopens after revitalisation
The Hyatt Centric Chicago O'Hare in the US has reopened after undergoing a revitalisation project with a modern aesthetic. Managed by Maverick Hotels & Restaurants, the hotel is situated less than two miles from Chicago's O'Hare International Airport. It offers 206 guest rooms, recreational facilities, and complimentary 24-hour airport shuttle services. Maverick Hotels & Restaurants founder and CEO Robert Habeeb said: 'More than just a place to stay, this hotel offers travellers a fresh and dynamic space where leisure and adventure collide under one roof. 'With modern design, elevated amenities, and unmatched proximity to the airport, we're proud to showcase what it means to stay in the centre of the action." The Hyatt Centric property now features reimagined guestrooms adorned with murals and a transformed lobby showcasing an art installation. Amenities at the property also include flexible meeting and event spaces, suitable for a variety of functions such as conferences and weddings. The hotel provides more than 7,600ft² of adaptable function and pre-function areas, complete with audiovisual capabilities. Hyatt Centric Chicago O'Hare general manager John Gill said: 'We're excited to welcome guests into this thoughtfully designed space, located a short distance from a variety of entertainment venues and the Donald E Stephens Convention Center. 'The hotel's lobby, guest rooms, meeting rooms, and restaurant will inspire guests to explore the city and put them at ease when they return to experience a stay worth sharing.' The hotel's signature Cima Restaurant offers both indoor dining and an al fresco experience on its 50-seat patio, which can be enclosed during warmer months. Cima has partnered with local suppliers such as Nichols Farm & Orchard, Ellis Family Farms, River Valley Ranch, and Slagel Farms to source ingredients. The hotel is in proximity to Rivers Casino, Rosemont Theatre, the Donald E Stevens Convention Center, and the Fashion Outlets of Chicago KOO Architecture and The Gettys Group are the design partners for the project. The reopening of Hyatt Centric Chicago O'Hare follows the earlier announcement this year by Hyatt Hotels and Birkla Investment Group regarding the planned opening of a 170-room Hyatt Centric-branded hotel in downtown Cincinnati, Ohio, US. "Hyatt Centric property in Chicago reopens after revitalisation" was originally created and published by Hotel Management Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
